LEUKO

Non-invasive white cell counts at the tip of your finger
Home-based self-test
Daily tracking
Reduced chemotherapy cycle time
Improved outcomes
White cell counts

Imagine a phone-sized blood cell counter that needs no blood. Innovative optics see through the skin, and count white cells as they flow past a miniature lens.

White cells count

The white cell count is the first line indicator for medical applications ranging from chemotherapy management to the detection of life threatening infection in a targeted world population of 4 billion people.

Team Leuko featured at the news in Spanish National Television, January 2016
About us

We learned that many cancer patients can tolerate a higher frequency of chemotherapy infusions than they typically get, and that with a higher frequency comes the high potential for better treatment outcomes. So we began to develop a personalized daily home blood test that will indicate when patients are ready for the next infusion ahead of the typical scheduling. Our optics-based test is non-invasive, detecting key informative blood cells through the skin without pain.. A potentially transformative improvement in chemotherapy management.

The key blood cells for our cancer application are also the key blood cells detected in acute infection. A simple test for these cells is sought throughout the resource poor regions of the world; especially where HIV-associated bacterial co-infection is endemic. This niche alone would account for approximately 40 million tests per year. There are approximately 4 billion people living in rural regions of our planet who currently have little or no access to testing for infection, which we've set out to provide.

The project is completing its proof of principle phase and entering its first clinical tests. By December 2016, two working prototypes completed their first round of clinical testing and design revision.

The Team
Carlos Castro-González, PhD
Project management and image analysis.

More info...
Aurelien Bourquard, PhD
Signal and image processing algorithms.

More info...
Ian Butterworth, MSc
Hardware design, prototyping, and technology validation.

More info...
Álvaro Sánchez-Ferro, MD
8-year experience in clinical practice and a background in research methodology.

More info...
Jason Tucker-Schwartz, PhD
Optical systems design and optimization.

More info...
Alberto Pablo-Trinidad, MSc
Computer vision and software development.

More info...
Ramon Gamble, MBA
Business development and commercialization path.

More info...
Donatello Castellana, PhD
Market research and regulatory affairs

More info...
Álvaro Martínez Higes, MBA
Entrepreneurial strategy.

More info...
Ola Kalinowska, BEng
Mechanical engineering

More info...
Collaborators
Clinical Collaborators
Carolina Cerrato, MD. Hospital La Paz, Madrid, Spain.
Rafael Flores, MD. Hospital de Fuenlabrada, Madrid, Spain.
Ephraim Hochberg, MD. Massachusetts General Hospital, Boston, USA.

Scientific Advisory Board
Martha Gray, PhD. Massachusetts Institute of Technology, Cambridge, USA. | Peter Hansen, PhD. Union Biometrica Technology Inc., Holliston, USA. | Petra Krauledat, PhD. PNPResearch Corporation, Cambridge, USA. | María J. Ledesma-Carbayo, PhD. Universidad Politécnica de Madrid, Madrid, Spain. | Jerome Mertz, PhD. Boston University, Boston, USA. | Arrate Muñoz-Barrutia, PhD. Universidad Carlos III, Madrid, Spain. | Francisca Mulero, PhD. Centro Nacional de Investigaciones Oncológicas, Madrid, Spain. | Timothy Padera, PhD. Harvard Medical School, Boston, USA. | Tom Vettenburg, PhD. Universidad Carlos III, Madrid, Spain.
News
Leuko wins the \"Tech Innovation Award\" at Rice Business Plan Competition.
Leuko named \"Innovation of the Year\", by MIT Technology Review Spain.
Leuko wins \"Impacto Salud\", a program to transform healthcare sponsored by social entrepreneurship network Ashoka and pharma Ipsen.
Aug 6, 2015
Leuko starts testing its prototype on chemotherapy patients at Massachusetts General Hospital, Boston, USA.
Leuko will hold an invited presentation at the IEEE Engineering in Biology and Medicine Conference, Milano (Italy), August 25-29, 2015.
Leuko selected as one of the new projects funded by the Coulter Foundation
Leuko selected as one of the new projects funded by the Center in Future Technologies in Cancer Care
Apr 23, 2015
Leuko pitched today to the Business Angels Network (BAN) in Madrid, Spain.
Dec 10, 2014
Leuko starts testing its first working prototype on human subjects at Hospital de Fuenlabrada, Madrid, Spain.
Leuko selected for MIT Translational Fellows Program 2014-15 (represented by Carlos Castro-González).
Leuko presents at the 2014 M+Vision Biomedical Innovation Conference in Madrid, Spain.